Who are the key players in the rapidly evolving rare neuro-immunological disease landscape and how do they impact our product’s development and positioning?

Our client was working to expand their rare neuroimmunological product’s label and venture into a range of additional rare indications, having to compete with both established and novel therapeutic agents from biotech and big pharma.

Eradigm monitored the rare neuroimmunological space for any new developments, covering medical conferences to provide strategically contextualised data analyses as well as routinely testing our hypothesis with experts in the HCP and competitor space. This enabled our client to constantly reassess their positioning within the landscape and ensure that their strategy can evolve and win in the space.